
Rocket Pharmaceuticals Inc
NASDAQ:RCKT

Intrinsic Value
The intrinsic value of one
RCKT
stock under the Base Case scenario is
2.24
USD.
Compared to the current market price of 2.7 USD,
Rocket Pharmaceuticals Inc
is
Overvalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Rocket Pharmaceuticals Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Rocket Pharmaceuticals Inc
Balance Sheet Decomposition
Rocket Pharmaceuticals Inc
Current Assets | 324.5m |
Cash & Short-Term Investments | 318.2m |
Other Current Assets | 6.3m |
Non-Current Assets | 146.6m |
PP&E | 80.4m |
Intangibles | 64.3m |
Other Non-Current Assets | 1.9m |
Free Cash Flow Analysis
Rocket Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Rocket Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-270.2m
USD
|
Operating Income
|
-270.2m
USD
|
Other Expenses
|
12.2m
USD
|
Net Income
|
-258m
USD
|
RCKT Profitability Score
Profitability Due Diligence
Rocket Pharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Score
Rocket Pharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
RCKT Solvency Score
Solvency Due Diligence
Rocket Pharmaceuticals Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Score
Rocket Pharmaceuticals Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RCKT Price Targets Summary
Rocket Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
RCKT
is 13.15 USD
with a low forecast of 2.02 USD and a high forecast of 38.85 USD.
Dividends
Current shareholder yield for RCKT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RCKT
stock under the Base Case scenario is
2.24
USD.
Compared to the current market price of 2.7 USD,
Rocket Pharmaceuticals Inc
is
Overvalued by 17%.